Sustained plasma TNF-α and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans
Identifieur interne : 001207 ( Main/Exploration ); précédent : 001206; suivant : 001208Sustained plasma TNF-α and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans
Auteurs : S. D. Lawn [États-Unis, Royaume-Uni] ; R. J. Shattock [Royaume-Uni] ; J. W. Acheampong [Ghana] ; R. B. Lal [États-Unis] ; T. M. Folks [États-Unis] ; G. E. Griffin [Royaume-Uni] ; S. T. Butera [États-Unis]Source :
- AIDS : (London) [ 0269-9370 ] ; 1999.
Descripteurs français
- KwdFr :
- Antigènes HLA-DR (immunologie), Antituberculeux (usage thérapeutique), Charge virale, Facteur de nécrose tumorale alpha (métabolisme), Ghana, Humains, Infections opportunistes liées au SIDA (immunologie), Infections opportunistes liées au SIDA (traitement médicamenteux), Infections opportunistes liées au SIDA (virologie), Tuberculose (), Tuberculose (immunologie), Tuberculose (traitement médicamenteux), Tuberculose (virologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification).
- MESH :
- immunologie : Antigènes HLA-DR, Infections opportunistes liées au SIDA, Tuberculose.
- isolement et purification : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- métabolisme : Facteur de nécrose tumorale alpha.
- traitement médicamenteux : Infections opportunistes liées au SIDA, Tuberculose.
- usage thérapeutique : Antituberculeux.
- virologie : Infections opportunistes liées au SIDA, Tuberculose.
- Pascal (Inist)
- Charge virale, Ghana, Humains, SIDA, Tuberculose, Virus HIV1, Infection opportuniste, Tuberculose, Complication, Chimiothérapie, Traitement, Plasma sanguin, Facteur nécrose tumorale α, Efficacité traitement, Immunorestauration, Exploration immunologique, Charge virale, Antituberculeux, Antibactérien, Homme.
- Wicri :
English descriptors
- KwdEn :
- AIDS, AIDS-Related Opportunistic Infections (drug therapy), AIDS-Related Opportunistic Infections (immunology), AIDS-Related Opportunistic Infections (virology), Antibacterial agent, Antitubercular Agents (therapeutic use), Antituberculous agent, Blood plasma, Chemotherapy, Complication, Ghana, HIV-1 (isolation & purification), HIV-1 virus, HLA-DR Antigens (immunology), Human, Humans, Immune reconstitution, Immunological investigation, Opportunistic infection, Treatment, Treatment efficiency, Tuberculosis, Tuberculosis (complications), Tuberculosis (drug therapy), Tuberculosis (immunology), Tuberculosis (virology), Tumor Necrosis Factor-alpha (metabolism), Tumor necrosis factor α, Viral Load, Viral load.
- MESH :
- chemical , immunology : HLA-DR Antigens.
- chemical , metabolism : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antitubercular Agents.
- geographic : Ghana.
- complications : Tuberculosis.
- drug therapy : AIDS-Related Opportunistic Infections, Tuberculosis.
- immunology : AIDS-Related Opportunistic Infections, Tuberculosis.
- isolation & purification : HIV-1.
- virology : AIDS-Related Opportunistic Infections, Tuberculosis.
- Humans, Viral Load.
Abstract
Objective: To determine the impact of treatment of tuberculosis on plasma HIV-1 load in African subjects and to correlate viral load with response to treatment and changes in immune activation. Design: Clinical and microbiological responses, immune activation parameters and plasma HIV-1 load were determined in 20 patients with pulmonary tuberculosis and HIV-1 coinfection in Ghana, West Africa during the first 3 months of anti-tuberculosis treatment. Methods: Plasma HIV-1 load and markers of immune activation were determined by commercially available assays. Human leukocyte antigen (HLA)-DR incorporation into the HIV-1 envelope was measured by using an immunomagnetic capture technique. Results: Treatment of tuberculosis resulted in significant improvements in weight and haemoglobin, a high sputum smear conversion rate and marked reductions in mean plasma tumour necrosis factor (TNF) receptor-1, interleukin-6 and C-reactive protein. Furthermore, incorporation of host HLA-DR into the HIV-1 envelope decreased; this also suggested a reduction in immune activation of the cells supporting viral replication. However, of importance with regard to AIDS pathogenesis, neither mean plasma TNF-α nor HIV-1 load decreased significantly. Conclusions: The failure of HIV-1 plasma load to decline significantly during the initial months of anti-tuberculosis treatment is associated with high, sustained systemic levels of TNF-α. The dissociation between the sustained levels of plasma TNF-α and the major reductions in other, diverse immune activation parameters may represent dysregulation of cytokine production in these African patients.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000149
- to stream PascalFrancis, to step Curation: 000000
- to stream PascalFrancis, to step Checkpoint: 000134
- to stream Main, to step Merge: 001297
- to stream PubMed, to step Corpus: 000433
- to stream PubMed, to step Curation: 000433
- to stream PubMed, to step Checkpoint: 000433
- to stream Ncbi, to step Merge: 000013
- to stream Ncbi, to step Curation: 000013
- to stream Ncbi, to step Checkpoint: 000013
- to stream Main, to step Merge: 001261
- to stream Main, to step Curation: 001207
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sustained plasma TNF-α and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans</title><author><name sortKey="Lawn, S D" sort="Lawn, S D" uniqKey="Lawn S" first="S. D." last="Lawn">S. D. Lawn</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, St. George's Hospital Medical School</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Shattock, R J" sort="Shattock, R J" uniqKey="Shattock R" first="R. J." last="Shattock">R. J. Shattock</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, St. George's Hospital Medical School</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Acheampong, J W" sort="Acheampong, J W" uniqKey="Acheampong J" first="J. W." last="Acheampong">J. W. Acheampong</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine, The School of Medical Sciences, University of Science and Technology</s1><s2>Kumasi</s2><s3>GHA</s3><sZ>3 aut.</sZ></inist:fA14><country>Ghana</country><wicri:noRegion>Kumasi</wicri:noRegion></affiliation></author><author><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R. B." last="Lal">R. B. Lal</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Folks, T M" sort="Folks, T M" uniqKey="Folks T" first="T. M." last="Folks">T. M. Folks</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Griffin, G E" sort="Griffin, G E" uniqKey="Griffin G" first="G. E." last="Griffin">G. E. Griffin</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, St. George's Hospital Medical School</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Butera, S T" sort="Butera, S T" uniqKey="Butera S" first="S. T." last="Butera">S. T. Butera</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">00-0065196</idno><date when="1999">1999</date><idno type="stanalyst">PASCAL 00-0065196 INIST</idno><idno type="RBID">Pascal:00-0065196</idno><idno type="wicri:Area/PascalFrancis/Corpus">000149</idno><idno type="wicri:Area/PascalFrancis/Curation">000000</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000134</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000134</idno><idno type="wicri:doubleKey">0269-9370:1999:Lawn S:sustained:plasma:tnf</idno><idno type="wicri:Area/Main/Merge">001297</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:10563708</idno><idno type="wicri:Area/PubMed/Corpus">000433</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000433</idno><idno type="wicri:Area/PubMed/Curation">000433</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000433</idno><idno type="wicri:Area/PubMed/Checkpoint">000433</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000433</idno><idno type="wicri:Area/Ncbi/Merge">000013</idno><idno type="wicri:Area/Ncbi/Curation">000013</idno><idno type="wicri:Area/Ncbi/Checkpoint">000013</idno><idno type="wicri:doubleKey">0269-9370:1999:Lawn S:sustained:plasma:tnf</idno><idno type="wicri:Area/Main/Merge">001261</idno><idno type="wicri:Area/Main/Curation">001207</idno><idno type="wicri:Area/Main/Exploration">001207</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sustained plasma TNF-α and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans</title><author><name sortKey="Lawn, S D" sort="Lawn, S D" uniqKey="Lawn S" first="S. D." last="Lawn">S. D. Lawn</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, St. George's Hospital Medical School</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Shattock, R J" sort="Shattock, R J" uniqKey="Shattock R" first="R. J." last="Shattock">R. J. Shattock</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, St. George's Hospital Medical School</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Acheampong, J W" sort="Acheampong, J W" uniqKey="Acheampong J" first="J. W." last="Acheampong">J. W. Acheampong</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine, The School of Medical Sciences, University of Science and Technology</s1><s2>Kumasi</s2><s3>GHA</s3><sZ>3 aut.</sZ></inist:fA14><country>Ghana</country><wicri:noRegion>Kumasi</wicri:noRegion></affiliation></author><author><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R. B." last="Lal">R. B. Lal</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Folks, T M" sort="Folks, T M" uniqKey="Folks T" first="T. M." last="Folks">T. M. Folks</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Griffin, G E" sort="Griffin, G E" uniqKey="Griffin G" first="G. E." last="Griffin">G. E. Griffin</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, St. George's Hospital Medical School</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Butera, S T" sort="Butera, S T" uniqKey="Butera S" first="S. T." last="Butera">S. T. Butera</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></analytic><series><title level="j" type="main">AIDS : (London)</title><title level="j" type="abbreviated">AIDS : (Lond.)</title><idno type="ISSN">0269-9370</idno><imprint><date when="1999">1999</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">AIDS : (London)</title><title level="j" type="abbreviated">AIDS : (Lond.)</title><idno type="ISSN">0269-9370</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>AIDS-Related Opportunistic Infections (drug therapy)</term><term>AIDS-Related Opportunistic Infections (immunology)</term><term>AIDS-Related Opportunistic Infections (virology)</term><term>Antibacterial agent</term><term>Antitubercular Agents (therapeutic use)</term><term>Antituberculous agent</term><term>Blood plasma</term><term>Chemotherapy</term><term>Complication</term><term>Ghana</term><term>HIV-1 (isolation & purification)</term><term>HIV-1 virus</term><term>HLA-DR Antigens (immunology)</term><term>Human</term><term>Humans</term><term>Immune reconstitution</term><term>Immunological investigation</term><term>Opportunistic infection</term><term>Treatment</term><term>Treatment efficiency</term><term>Tuberculosis</term><term>Tuberculosis (complications)</term><term>Tuberculosis (drug therapy)</term><term>Tuberculosis (immunology)</term><term>Tuberculosis (virology)</term><term>Tumor Necrosis Factor-alpha (metabolism)</term><term>Tumor necrosis factor α</term><term>Viral Load</term><term>Viral load</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antigènes HLA-DR (immunologie)</term><term>Antituberculeux (usage thérapeutique)</term><term>Charge virale</term><term>Facteur de nécrose tumorale alpha (métabolisme)</term><term>Ghana</term><term>Humains</term><term>Infections opportunistes liées au SIDA (immunologie)</term><term>Infections opportunistes liées au SIDA (traitement médicamenteux)</term><term>Infections opportunistes liées au SIDA (virologie)</term><term>Tuberculose ()</term><term>Tuberculose (immunologie)</term><term>Tuberculose (traitement médicamenteux)</term><term>Tuberculose (virologie)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>HLA-DR Antigens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antitubercular Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes HLA-DR</term><term>Infections opportunistes liées au SIDA</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antituberculeux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Viral Load</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Charge virale</term><term>Ghana</term><term>Humains</term><term>SIDA</term><term>Tuberculose</term><term>Virus HIV1</term><term>Infection opportuniste</term><term>Tuberculose</term><term>Complication</term><term>Chimiothérapie</term><term>Traitement</term><term>Plasma sanguin</term><term>Facteur nécrose tumorale α</term><term>Efficacité traitement</term><term>Immunorestauration</term><term>Exploration immunologique</term><term>Charge virale</term><term>Antituberculeux</term><term>Antibactérien</term><term>Homme</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To determine the impact of treatment of tuberculosis on plasma HIV-1 load in African subjects and to correlate viral load with response to treatment and changes in immune activation. Design: Clinical and microbiological responses, immune activation parameters and plasma HIV-1 load were determined in 20 patients with pulmonary tuberculosis and HIV-1 coinfection in Ghana, West Africa during the first 3 months of anti-tuberculosis treatment. Methods: Plasma HIV-1 load and markers of immune activation were determined by commercially available assays. Human leukocyte antigen (HLA)-DR incorporation into the HIV-1 envelope was measured by using an immunomagnetic capture technique. Results: Treatment of tuberculosis resulted in significant improvements in weight and haemoglobin, a high sputum smear conversion rate and marked reductions in mean plasma tumour necrosis factor (TNF) receptor-1, interleukin-6 and C-reactive protein. Furthermore, incorporation of host HLA-DR into the HIV-1 envelope decreased; this also suggested a reduction in immune activation of the cells supporting viral replication. However, of importance with regard to AIDS pathogenesis, neither mean plasma TNF-α nor HIV-1 load decreased significantly. Conclusions: The failure of HIV-1 plasma load to decline significantly during the initial months of anti-tuberculosis treatment is associated with high, sustained systemic levels of TNF-α. The dissociation between the sustained levels of plasma TNF-α and the major reductions in other, diverse immune activation parameters may represent dysregulation of cytokine production in these African patients.</div></front></TEI><affiliations><list><country><li>Ghana</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Géorgie (États-Unis)</li></region><settlement><li>Londres</li></settlement></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Lawn, S D" sort="Lawn, S D" uniqKey="Lawn S" first="S. D." last="Lawn">S. D. Lawn</name></region><name sortKey="Butera, S T" sort="Butera, S T" uniqKey="Butera S" first="S. T." last="Butera">S. T. Butera</name><name sortKey="Folks, T M" sort="Folks, T M" uniqKey="Folks T" first="T. M." last="Folks">T. M. Folks</name><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R. B." last="Lal">R. B. Lal</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Lawn, S D" sort="Lawn, S D" uniqKey="Lawn S" first="S. D." last="Lawn">S. D. Lawn</name></region><name sortKey="Griffin, G E" sort="Griffin, G E" uniqKey="Griffin G" first="G. E." last="Griffin">G. E. Griffin</name><name sortKey="Shattock, R J" sort="Shattock, R J" uniqKey="Shattock R" first="R. J." last="Shattock">R. J. Shattock</name></country><country name="Ghana"><noRegion><name sortKey="Acheampong, J W" sort="Acheampong, J W" uniqKey="Acheampong J" first="J. W." last="Acheampong">J. W. Acheampong</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001207 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001207 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:00-0065196
|texte= Sustained plasma TNF-α and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans
}}
| This area was generated with Dilib version V0.6.31. |  |